1286650

フルベストラント

United States Pharmacopeia (USP) Reference Standard

• 別名: (7α、17β)-7-[9-[(4,4,5,5,5-ペンタフルオロペンチル)スルフィニル]ノニル]エストラ-1,3,5(10)-トリエン-3,17-ジオール, ICI 182,780, ZD 182780, ZD 9238, ZM 182780, ファスロデックス
• 実験式（ヒル表記法）: C₃₂H₄₇F₅O₃S
• CAS番号: 129453-61-8
• 分子量: 606.77
• MDL番号: MFCD00903953
• UNSPSCコード: 41116107
• PubChem Substance ID: 329749913
• NACRES: NA.24

特性

• グレード: pharmaceutical primary standard
• APIファミリー: fulvestrant
• メーカー／製品名: USP
• アプリケーション: pharmaceutical (small molecule)
• フォーマット: neat
• 保管温度: 2-8°C
• SMILES記法: [H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc24
• InChI: 1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
• InChI Key: VWUXBMIQPBEWFH-WCCTWKNTSA-N
• 遺伝子情報: human ... ESR1(2099) , ESR2(2100)

詳細

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

• Targeted Radiation Drug for Breast Cancer: Fulvestrant was utilized in fluorocarbon nanoparticles combined with iodine-131, demonstrating potential as a targeted radiation drug for endocrine therapy in breast cancer treatment, enhancing the applicability of Fulvestrant in advanced therapeutic approaches (Zhi et al., 2024).


• Pharmacological Insights: A comprehensive review discussed novel oral selective estrogen receptor degraders, including Fulvestrant, detailing their mechanism and efficacy in breast cancer treatment, providing crucial insights for ongoing pharmaceutical research and development (Guglielmi et al., 2024).


• Quantification in Clinical Practice: Development of an LC-MS/MS method for the simultaneous quantification of four hormone therapy drugs, including Fulvestrant, in breast cancer patients supports its clinical application and monitoring, ensuring effective patient management and therapy optimization (Mansour et al., 2024).

生物化学的／生理学的作用

フルベストラント(ICI 182,780)はエストロゲンレセプタ-を選択的にダウンレギュレ-トするER減少薬(selective estrogen receptor down-regulator :SERD)です。フルベストラントは高親和性エストロゲン受容体アンタゴニストです。IC₅₀=0.29 nMフルベストラントはin vitro 、in vivo の双方においてアゴニスト作用を持たない、最初の「純粋な」抗エストロゲン剤です

アナリシスノート

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

その他情報

Sales restrictions may apply.

安全性情報

• ピクトグラム: GHS08,GHS09
• シグナルワード: Danger
• 危険有害性情報: H360Df,H362,H410
• 注意書き: P202 - P260 - P263 - P264 - P273 - P308 + P313
• 危険有害性の分類: Aquatic Chronic 1 - Lact. - Repr. 1B
• 保管分類コード: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable